Skip to main content
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1972 Dec;35(6):873–876. doi: 10.1136/jnnp.35.6.873

Effect of dosage increments on blood phenytoin concentrations

F Bochner 1, W D Hooper 1, J H Tyrer 1, M J Eadie 1
PMCID: PMC494195  PMID: 4647859

Abstract

Blood phenytoin (diphenylhydantoin) concentrations were measured after each dosage change in 12 epileptic patients who were given increasing oral doses of phenytoin. In each of these patients a dosage increment beyond the dosage that produced a blood phenytoin level of 6-9 μg/ml. caused a disproportionately great increase in the blood concentration of drug. This effect might be expected if the limit of the body's capacity to metabolize phenytoin were being reached. As oral dosages were increased in one patient, measurements of the rate of urinary excretion of phenytoin metabolite showed that the phase of rapid rise in blood phenytoin concentration coincided with a failure to increase the rate of phenytoin metabolite excretion. Awareness of the non-linear relation between oral dose and blood concentration of phenytoin in the individual patient, and realization that the phase of rapid rise in blood phenytoin concentration occurs through the `therapeutic' range of 10-20 μg/ml., is of importance to those who use blood phenytoin levels as a guide to the adequacy of anticonvulsant therapy.

Full text

PDF
873

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121–134. doi: 10.1002/cpt1970111121. [DOI] [PubMed] [Google Scholar]
  2. BUCHTHAL F., SVENSMARK O. Aspects of the pharmacology of phenytoin (dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy. Epilepsia. 1960 Jun;1:373–384. doi: 10.1111/j.1528-1157.1959.tb04274.x. [DOI] [PubMed] [Google Scholar]
  3. Chang T., Savory A., Glazko A. J. A new metabolite of 5,5-diphenylhydantoin (Dilantin). Biochem Biophys Res Commun. 1970 Feb 6;38(3):444–449. doi: 10.1016/0006-291x(70)90733-3. [DOI] [PubMed] [Google Scholar]
  4. Kutt H., McDowell F. Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients. JAMA. 1968 Mar 11;203(11):969–972. [PubMed] [Google Scholar]
  5. MacGee J. Rapid determination of diphenylhydantoin in blood plasma by gas-liquid chromatography. Anal Chem. 1970 Mar;42(3):421–422. doi: 10.1021/ac60285a024. [DOI] [PubMed] [Google Scholar]
  6. Remmer H., Hirschmann J., Greiner I. Die Bedeutung von Kumulation und Elimination für die Dosierung von Phenytoin (Diphenylhydantoin) Dtsch Med Wochenschr. 1969 Jun 13;94(24):1265–1272. doi: 10.1055/s-0028-1111205. [DOI] [PubMed] [Google Scholar]
  7. Wallace J. E. Microdetermination of diphenylhydantoin in biological specimens by ultraviolet spectrophotometry. Anal Chem. 1968 May;40(6):978–980. doi: 10.1021/ac60262a023. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES